Table 2 Treatment responses of whole group and different subgroups
Objective response | Disease control | Median PFS | |||
|---|---|---|---|---|---|
No. (%) | 95%CI | No. (%) | 95%CI | Months (95% CI) | |
Whole group (n = 16) | 11 (68.8) | 41.3 to 89.0 | 15 (93.8) | 69.8 to 99.8 | 14.0 (4.3 to 23.7) |
Major EGFR mutation | |||||
G719X (n = 9) | 6 (66.7) | 29.9 to 92.5 | 8 (88.9) | 51.8 to 99.7 | 14.0 (4.2 to 23.8) |
L861Q (n = 4) | 2 (50.0) | 6.8 to 93.2 | 4 (100.0) | 39.8 to 100.0 | 6.5 (0 to 20.7) |
Evaluable Brain metastasis (n = 6a) | 5 (83.3) | 35.9 to 99.6 | 6 (100.0) | 54.1 to 100.0 | 9.0 (6.9 to 11.1) |